Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11961359 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL11981760 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL11961356 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL5839806 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL345904 | 1.00 | CA2 (0.36) | CA2CA1CA9 | |
| SCHEMBL12060575 | 0.92 | CA2 (0.39) | CA2CA1CA9 | |
| SCHEMBL20367420 | 0.83 | CA1 (0.31) | CA2CA1CA9 | |
| SCHEMBL15678414 | 0.81 | CA2 (0.45) | CA2CA1CA9 | |
| SCHEMBL29525029 | 0.81 | CA1 (0.31) | CA2CA1CA9 | |
| SCHEMBL13592460 | 0.80 | CA2 (0.44) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227527-B2 | Process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2025-02-18 | — | — | US | disclosed |
| EP-4083026-A1 | PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2022-11-02 | — | — | EP | disclosed |
| US-20210284662-A1 | PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2021-09-16 | — | — | US | disclosed |
| US-20210284662-A1 | PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2021-09-16 | — | — | US | disclosed |
| EP-3820853-A1 | PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2021-05-19 | — | — | EP | disclosed |
| EP-3255043-B1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2021-01-20 | — | — | EP | disclosed |
| WO-2020012372-A1 | PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012372-A1 | PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2020-01-16 | — | — | WO | disclosed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | disclosed |
| EP-3141235-A1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3-METHYLAZETIDINE-L -SULFONAMIDE | IP Gesellschaft für Management mbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| WO-2000026179-A1 | BIODEGRADABLE NONIONIC CONTRAST MEDIA | BIOPHYSICA INC (US) | 2000-05-11 | — | — | WO | disclosed |
| US-6054117-A | NUCLEAR MAGNETIC RESONANCE CONTRAST MEDIA FOR DIAGNOSTICS AND THERAPY; PHYSIOLOGICALLY ACCEPTABLE EXCRETION | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| US-5980864-A | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | SCHERING AKTIENGELLSELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| US-5911971-A | NMR CONTRAST MEDIA WHICH CAN MARK THE VASAL SPACE (BLOOD POOL AGENT); UNIFORM AND HIGH ENOUGH MOLECULAR WEIGHT TO BE RETAINED IN BLOOD VESSEL BUT SMALL ENOUGH TO BE ELIMINATED BY THE KIDNEY; POLYAMINOAMIDES; MACROMOLECULES | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-06-15 | — | — | US | disclosed |
| US-5876698-A | Macrocyclic polymer complexing agents, their complexes, process for their production and pharmaceutical agents containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-02 | — | — | US | disclosed |
| US-5650136-A | Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-22 | — | — | US | disclosed |
| US-5410043-A | Chemical intermediate for metal complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-04-25 | — | — | US | disclosed |
| US-5364614-A | Cascade polymer bound chelating compounds, their chelates and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | disclosed |
| US-4570007-A | 2-Amino-1-(1,2-dioxolan-4-yl)ethanol compounds, their preparation and use | SHERING AKTIENGESELLSCHAFT (DE) | 1986-02-11 | — | — | US | disclosed |
| US-4547357-A | OPACIFIER FOR X-RAY DIAGNOSIS | SCHERING, AKTIENGESELLSCHAFT (DE) | 1985-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284662-A1 | PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES | TMCO1, CALCA, CA2 | CA2 3/4885CA1 15/4885CA9 46/4885 |
| US-12227527-B2 | Process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes | TMCO1, CA2, CALCA | CA2 2/4885CA1 15/4885CA9 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.